CTRI/2019/02/017548进行中（未招募）2 期
To evaluate the efficacy of therapy administered based on guidance obtained from integrative molecular analysis of cell free nucleic acids and in vitro chemosensitivity analysis of circulating tumor cells, aimed at improving availability of therapy options and treatment outcomes in relapsed/refractory metastatic solid organ tumors with unavailability of de novo tissue biopsies. - LIQUID-IMPACT
Datar Cancer Genetics Limited0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •For Inclusion, an individual must meet all of the following criteria:
- •1.Age â?? 18 to 70 years (male or female);
- •2.Refractory/relapsed, advanced/unresectable/metastatic histologically documented solid organ malignancy
- •3.Should have ECOC score of maximum 2 and a life expectancy of at least 3 months
- •4.Patient should have progressed on at least one SOC lines of therapy OR have no further SOC option/ option is beyond financial reach OR there must not be other approval/standard therapy available that has been shown to prolong overall survival OR therapy naïve patients where no agreed upon standard of care (SOC) options exist OR patients who cannot receive other standard therapy that has been shown to prolong overall survival due to medical issues will be eligible. (SOC lines would include surgery / RT / Cytotoxic therapy / targeted therapy)
- •5.If the patient is currently receiving therapy, the clinician must have assessed that the current therapy is no longer benefitting the patient prior to enrolling
- •6.Patient should be willing and fit for requisite blood or body fluid sampling required for study purpose e.g. ascitic fluid / pleural fluid/ CSF etc. as the case may be;
- •7.Patient should be physically and financially able to undertake treatment as may be advised after the analysis by DCGL with good compliance history in the past;
- •8.Patient should be willing and ready for baseline PET Scan and/or CT and/or USG and/or MRI and follow-up scans (usually the first follow-up scan is after 30 days followed by further scans at 75 days and 120 days);
- •9.Patient is willing and can tolerate cytotoxic and targeted therapy (labelled / off-label / repurposed / natural tumor inhibiting supplements);
- •10.Female patient is not pregnant / lactating;
- •11.Provision of signed and dated informed consent form
- •12.Stated willingness to comply with all study procedures
- •13.Patients must have measurable disease on radiological imaging post biopsy to monitor treatment response
- •14.Adequate organ function defined as:
- •a)Absolute neutrophil count >= 1,000/μL
- •b)Platelet count >= 50,000/μL
- •c)Total bilirubin <= 1.5x institutional upper limit of normal (IULN)
- •d)AST and ALT <= 2x IULN
- •e)Creatinine <= 2x IULN
- •f)Creatinine clearance >= 45 mL/min/1.73m2 for participants with creatinine levels above IULN
- •g)Albumin >= 2.5 g/dL
- •h)Prothrombin time (PT) and PTT 80% to 120% of institutional normal range
- •i)Left Ventricular Shortening Fraction (LVSF) >= 28% confirmed by echocardiogram (ECHO), or Left Ventricular Ejection Fraction (LVEF) >= 45% confirmed by echocardiogram or Multiple Uptake Gated Acquisition (MUGA).
排除标准
- •1.Patients who fail to meet all of the iclusion criteria will be excluded. Failing to meet any single criteria would be sufficient grounds for exclusion.
- •2.Prior malignancy other than types included in study
- •3.Active or latent hepatitis B or active hepatitis C (test within 8 weeks of screening), or any uncontrolled infection at screening
- •4.Human Immunodeficiency Virus (HIV) positive test within 8 weeks of screening.
- •5.Serious co-morbidities such as, but not limited to severe cardiac failure severe pulmonary compromise or severe and active infections, HIV, HPV, HBV, HCV, Tuberculosis etc.
- •6.Patient has an investigational medicinal product within the last 30 days prior to screening.
- •7.Pregnant or nursing women.
- •8.Psychiatric illness with potential to affect study compliance
研究者
相似试验
进行中（未招募）
1 期
Evaluation of the efficacy of antibiotic treatments associated with the Nebcine® as intravenous injection only and / or monitoring of aerosols of Tobi® in order to optimize the therapeutic management of exacerbations in patients with cystic fibrosis .EUCTR2014-003882-10-FRCHRU de Lille
已完成
2 期
A Clinical study on cervical spondylosis using thengaai thuruval ottradam (external therapy)CTRI/2021/02/031542Government Siddha medical college and hospital40
招募中
不适用
Effect of trutyadi churna in amavata with special reference to rheumatoid arthritis.CTRI/2021/08/035463DR VISHNUPRIYA SEETHARAM
尚未招募
3 期
Ayurvedic medicine-siddartakadi yoga in depressioCTRI/2024/04/065341I
已完成
2 期
Comparison of efficacy of oral Levamisole and Formoterol+Budesonide inhaler with standard treatment of Corona infection.IRCT20200324046852N1Fasa University of Medical Sciences30